{"id":"W2984221112","doi":"10.1016/j.jhep.2019.11.003","title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡","year":2019,"lang":"en","type":"review","venue":"Journal of Hepatology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Barts and The London School of Medicine and Dentistry; Perelman School of Medicine, University of Pennsylvania; Universitätsklinikum Hamburg-Eppendorf; National Institutes of Health; European Association for the Study of the Liver; National and Kapodistrian University of Athens; Università degli Studi di Parma; University of Toronto; University College London; National Institute for Health and Care Research; Universitätsklinikum Essen; Università degli Studi di Milano; University of Pennsylvania; Barts Charity; Universität Duisburg-Essen; Roche; Gilead Sciences; Deutsches Zentrum für Infektionsforschung; Universität Hamburg; Bristol-Myers Squibb","keywords":"Medicine; HBsAg; Clinical endpoint; Clinical trial; Internal medicine; Surrogate endpoint; Hepatitis B; Discontinuation; HBeAg; Chronic hepatitis; cccDNA; Hepatitis B virus; Gastroenterology; Immunology; Virus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1358776,0.004047289,0.01485513,0.006488854,0.001005931,0.009108445,0.008674042,0.01217728,0.02079452],"category_scores_gemma":[0.1716333,0.002876295,0.02308442,0.005609781,0.001648084,0.003861511,0.00374475,0.01605179,0.01381103],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006139535,"about_ca_system_score_gemma":0.01971495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005998709,"about_ca_topic_score_gemma":0.01220835,"domain_scores_codex":[0.8728427,0.08848561,0.02286282,0.00217879,0.01207213,0.001557947],"domain_scores_gemma":[0.8036813,0.1232551,0.03246493,0.005271544,0.03154707,0.003780028],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006305306,0.0002012847,0.0008156252,0.1090057,0.004478333,0.0001551819,0.0002348439,0.00151978,0.0008729165,0.01096915,0.5565374,0.3089043],"study_design_scores_gemma":[0.01368383,0.0008609096,0.006303933,0.1883951,0.01089133,0.0003758572,0.0001272978,0.001697402,0.0009730177,0.020716,0.7556974,0.0002779154],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001363977,0.6799228,0.05971504,0.07842516,0.02786964,0.05147623,0.06518476,0.004380815,0.03166168],"genre_scores_gemma":[0.01430217,0.311747,0.3909326,0.08648659,0.00921738,0.1191266,0.0407362,0.001925604,0.02552585],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8641225,"threshold_uncertainty_score":0.7185978,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5009424665261447,"score_gpt":0.5366977400755869,"score_spread":0.03575527354944219,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}